Nursing Care of Patients with Multiple Sclerosis During Immunomodulatory Treatment of First-line Drugs
Keywords
multiple sclerosis, immunomodulatory first-line drugs, nursing careAbstract
Multiple Sclerosis (SM) is a chronic demyelinating disease of the central nervoussystem with immunological background. MS is most frequently diagnosed in people between 20 and 40 years of age, and this isinmost cases the relapsing — remitting form of the disease. Immunomodulatory therapy used in these patients isto reduce the frequency of relapses, thus the inhibition of progressive neurological disability and improvement of quality of life of patients is reached. At present in Poland the registered drugs in the treatment
of immunomodulatory relapsing — remitting form of multiple sclerosis include: interferons, glatiramer acetate, natalizumabifingolimod. The condition for the effectiveness of this therapy is to follow the rules of procedure by the patient during the entire treatment period. The role of nurses in this area is very important. This paper presents the role of nurses in the course of immunomodulatory therapy of first-line drugs. These drugs include interferons and glatiramer acetate. Since the start of therapy by the patient, the nurse takes an active part in educating, monitoring, and providing support to the patient during the entire treatment period. Nursing interventions in these areas are varied and depend on the type of treatment, which in a given patient has been applied. (PNN 2013; 2(5): 223–227)
References
Losy J. Stwardnienie Rozsiane. Czelej, Lublin 2013.
Selmaj K. Stwardnienie rozsiane. Termedia, Poznań 2006.
Levis P. Rowland, NeurologiaMerritta Elsevier Urban & Partner, Wrocław2005; Tom III, 963–987.
Rudick R.A., Goelz S.E. Beta-interferon for multiple sclerosis. Experimental Cell Research. 2011;15;317(9): 1301–1311.
Zang Y., Hong J., Robinson R. Immune regulatory properties and interaction of copolymer-I and beta-interferon 1a in multipkle sclerosis. J Neuroimmunol. 2003;137 (1–2):144–153.
Ziemssen T., Kuempfel T., Klinkert W.E.F. Glatiramer acetate-specific T-helper 1 and 2-type cel lines produce BDNF: implication for multiple sclerosis therapy. Brain 2002;125: 2381–2391.
Durelli L., Oggro A., Verdun E. i wsp. Interferon-beta dose and efficacy: the OPTIMS study. NeurolSci. 2001;22: 201–203.
Selmaj K. Stwardnienie rozsiane — kryteria diagnostyczne i naturalny przebieg choroby. Polski Przegląd Neurologiczny. 2005;(3):99–105.
Wilkiewicz M. Diagnoza pielęgniarska i plan opieki nad chorym ze stwardnieniem rozsianym. W: Jaracz K., Kozubski W. (Red.). Pielęgniarstwo neurologiczne, PZWL, Warszawa 2008;257–264.
Wiszniewska M., Żdanowicz A. Udział pielęgniarki w leczeniu immunomodulacyjnym i wspomagającym pacjentów ze stwardnieniem rozsianym. Państwowa Wyższa Szkoła Zawodowa im. S. Staszica w Pile, 2009.
Halper J. The Evolving Role of the Nurse in the Treatment of Muliple sclerosis. Journal of Neuroscience Nursing. 2009;41(4):1–13.
Rudic R.A., Goelz S.E., Beta-interferon for multiple sclerosis. Experimentalcellresearch. 2011;15;317(9): 1301–1311.
Potemkowski A. Psychologiczne aspekty stwardnienia rozsianego. Termedia, Poznań 2010.
Potemkowski A, Tyburski E, Wąsik M, Stencelewicz E. Komunikacja z pacjentem ze stwardnieniem rozsianym. Neurologia Praktyczna. 2013;1(70).
Downloads
Published
How to Cite
Issue
Section
License
![Creative Commons License](http://i.creativecommons.org/l/by-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 653
Number of citations: 0